Clinical trials: Ticagrelor
Healthy
Study to Assess Effect of Cyclosporine on the Blood Levels of Ticagrelor
The purpose of this study is to assess the effect of Cyclosporine on the blood levels of Ticagrelor.
- Trial name
- NCT01504906
- Testing
- cyclosporine, ticagrelor
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Ischemic Stroke, Transient Ischemic Attack
Ticagrelor Based De-Escalation of Dual Antiplatelet Therapy in Ischemic Stroke
This is a randomized, controlled, outcome assessor blind, parallel group design pilot study on 100 patient with diagnosis of ischemic stroke admitted in Bou-Ali Sina Hospital, Sari,Iran.The aim of study is to compare the efficacy…
- Trial name
- DEDAPT-TICA (NCT06653348)
- Testing
- Ticagrelor 60 + Aspirin, Ticagrelor 90 + aspirin
- Where
- Iran
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Mazandaran University of Medical Sciences
Bioavailability Heathy Volunteers
Study to Investigate if the Uptake of Ticagrelor Into the Body Differs Depending on Method of Administration.
Study to investigate if the uptake of Ticagrelor into the body differs depending on method of administration.
- Trial name
- NCT01887626
- Testing
- Ticagrelor 90 mg whole tablet, Ticagrelor 90 mg tablet crushed, Dispersed ticagrelor 90 mg tablet suspended in water - nasogastric tube
- Where
- United Kingdom
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Bioequivalence, Healthy Japanese Subjects
Study to Assess the Bioequivalence Between Ticagrelor Orodispersible Tablets and Ticagrelor Immediate-release Tablets in Japanese Subjects
This study will be an open-label, randomised, three-period, three-treatment, crossover study in healthy Japanese male and female of non-childbearing potential subjects, performed at a single study centre.
- Conditions
- Bioequivalence, Healthy Japanese Subjects, Pharmacokinetics
- Trial name
- NCT02436577
- Testing
- Ticagrelor OD tablet (90 mg single dose) administered with 150 mL of water, Ticagrelor OD tablet (90 mg single dose) administered without water, Ticagrelor IR tablet (90 mg) administered with 150 mL of water
- Where
- United Kingdom
- Volunteers
- 51 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Thrombosis
To Evaluate the Safety and Tolerability of Combined Administration of SHR2285 Tablets With Aspirin, Clopidogrel or Ticagrelor in Healthy Subjects
The study is a single-center，randomized, doubled-blinded, placebo-controlled, Only for SHR2285 Phase I trial. This study intends to enroll 52 healthy subjects, regardless of gender.
- Trial name
- NCT04945616
- Where
- China
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Acute Coronary Syndrome
The Effect of Clopidogrel and Ticagrelor With and Without Acetylsalicylic Acid (ASA) on Hemostatic System Activation at the Site of Plug Formation in Vivo in Man
Background: Coronary heart disease is the most common cause of death in industrialized countries. Revascularisation by percutaneous coronary angioplasty or thrombolysis is the main principle for treatment of the acute coronary…
- Trial name
- NCT02120092
- Testing
- Clopidogrel, Ticagrelor, ASA
- Where
- Austria
- Volunteers
- 89 people, healthy volunteers welcome
- Sponsor
- Medical University of Vienna
Healthy
Comparative Bioavailability Study Between Ticagrelor and ASA Administered Individually or in Combination.
Study conducted to determine and compare the relative bioavailability of two solid oral formulations (reference versus test) of the non-fixed combination of Ticagrelor 90 mg (Brilinta by AstraZeneca S.A.
- Trial name
- NCT07444164
- Testing
- A1: Ticagrelor / Acetylsalicylic acid in fixed dose combination capsule. (Laboratorios Silanes S.A. de C.V.), A2: Ticagrelor (BRILINTA®, AstraZeneca S.A. de C.V.) A3: Acetylsalicylic Acid (ASPIRINA JUNIOR®, Bayer de México S.A. de C.V.)
- Where
- Mexico
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Laboratorios Silanes S.A. de C.V.
Kidney Failure, Chronic
Pharmacokinetics, Pharmacodynamics, and Safety Study of Ticagrelor in Hemodialysis Patients and Healthy Subjects
A phase I, open-label study comparing the pharmacokinetics, pharmacodynamics, safety and tolerability of ticagrelor in hemodialysis patients to healthy subjects with normal renal function.
- Trial name
- NCT02022748
- Testing
- ticagrelor
- Where
- 2 sites in United States
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Chronic Kidney Diseases, Heart Attack
Chronic Kidney Disease (CKD) Platelet Study
This study evaluates how aspirin, clopidogrel and ticagrelor work in people with chronic kidney disease (CKD) compared to people with normal kidneys.
- Conditions
- Chronic Kidney Diseases, Heart Attack, Stroke, Ischemic
- Trial name
- NCT03649711
- Testing
- Ticagrelor 90mg, Clopidogrel 75mg, Aspirin 81 mg
- Where
- 2 sites in United States
- Volunteers
- 76 people, healthy volunteers welcome
- Sponsor
- University of Arkansas
Ischemia
The Effect of Ticagrelor With or Without Atorvastatin on Endothelial Function in Healthy Males
To test the effect of atorvastatin or placebo in combination with ticagrelor on ACh-induced vasodilatation of the forearm resistance vasculature as assessed by forearm blood flow (FBF) measurement before and 10 min after a 20 min…
- Trial name
- NCT02910778
- Testing
- Atorvastatin, Ticagrelor
- Where
- Austria
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Medical University of Vienna
Healthy
Study to Evaluate the Safety, Tolerability, PK, and PD of PB2452 in Healthy Volunteers
This is a Phase 1, first-in-human, randomized, double-blind, placebo-controlled, single ascending dose, sequential group study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of PB2452 with and…
- Trial name
- NCT03492385
- Testing
- PB2452 Infusion, Ticagrelor Oral Tablet - Pre-Treatment, Ticagrelor Oral Tablet - Pre-Treatment and Post-Treatment
- Where
- United States
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- SFJ Pharmaceuticals, Inc.
Insomnia
A Drug-drug Interaction Study of YZJ-1139 Tablets and Ticagrelor Tablets in Healthy Subjects
Primary Objective : To evaluate the effect of ticagrelor tablets on the pharmacokinetic characteristics of YZJ-1139 in healthy subjects; Secondary Objective: To evaluate the safety of ticagrelor tablets in combination with…
- Trial name
- NCT06671470
- Testing
- YZJ-1139 tablets, Ticagrelor Tablets
- Where
- China
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- Shanghai Haiyan Pharmaceutical Technology Co., Ltd.
Healthy
Dose Adaptation to Offset the Interaction Between Ticagrelor and Ritonavir by Population-based PK Modeling
Ticagrelor is a new generation antiplatelet agent with higher efficacy as compared to clopidogrel and prasugrel in treatment of patients with moderate and high ischemic risks.
- Trial name
- NCT02435563
- Testing
- ticagrelor 180 mg administrated alone, Ticagrelor adjusted dose + ritonavir 100mg
- Where
- Switzerland
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- University Hospital, Geneva
Platelet Reactivity
Low-dose of Ticagrelor and Standard-dose Clopidogrel on Platelet Effects in Chinese Patients With Stable CAD.
Ticagrelor has been demonstrated to provide a more rapid and more powerful inhibition of platelet aggregation compared with clopidogrel in coronary artery disease (CAD) patients.
- Trial name
- NCT03679091
- Testing
- low-dose ticagrelor, Clopidogrel
- Where
- China
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- First Affiliated Hospital of Harbin Medical University
Coronary Artery Disease
Reversal of the Anti-platelet Effects of Ticagrelor
The purpose of this study is to determine the proportion of untreated donor platelets required to fully reverse the platelet inhibitory effects of ticagrelor and aspirin in healthy persons and patients with coronary artery…
- Trial name
- REVERSAL (NCT02383771)
- Testing
- Ticagrelor, Aspirin + Ticagrelor, Control
- Where
- China
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Renal Impairment
Study to Investigate the Effects of AZD6140 in Patients With Renal Impairment and in Healthy Volunteers
The main purpose of this study is to examine how AZD6140 affects patients with severe kidney disease compared to volunteers with normal kidneys. Subjects in the study will receive one dose of AZD6140.
- Trial name
- NCT00733265
- Testing
- AZD6140
- Where
- 4 sites in United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Healthy Volunteers
A Study of the Effect of Epinephrine on Platelet Reactivity in Subjects Treated With Ticagrelor
The study is an experimental observational study in ten healthy volunteers. Based on an in vitro study, it is hypothesize that a low dose epinephrine infusion will improve platelet function in healthy volunteers who have received…
- Trial name
- NCT03441412
- Testing
- Ticagrelor 90mg, Epinephrine, Metoprolol
- Where
- Sweden
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Vastra Gotaland Region
Pharmacokinetics
An Open-Label, Single and Multiple Dose Pharmacokinetic Study of 90 mg and 180 mg Doses of AZD6140 in Healthy Volunteers
This will be a single centre study conducted at the 3rd hospital affiliated to Peking University. Approximately 24 healthy Chinese volunteers, male and female, will be recruited to obtain at least 20 evaluable volunteers.
- Trial name
- NCT00721448
- Testing
- AZD6140
- Where
- China
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Coronary Artery Disease, Healthy Participants
A Study to Evaluate BMS-986141 Added on to Aspirin or Ticagrelor or the Combination, on Thrombus Formation in a Thrombosis Chamber Model in Participants With Stable Coronary Artery Disease and Healthy Participants
The purpose of this study is to assess the effectiveness, safety and tolerability of BMS-986141 added on to aspirin or ticagrelor or the combination on thrombus formation in both healthy participants and participants with stable…
- Trial name
- NCT05093790
- Testing
- Ticagrelor, BMS-986141, Aspirin
- Where
- United Kingdom
- Volunteers
- 58 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
Cardiovascular Disease
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of AZD3366 in Healthy Subjects, Japanese and Chinese Subjects
Part A of this study is a Phase 1, First-in-human (FiH), randomized, single-blind, placebo controlled study to assess the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of AZD3366 following single…
- Trial name
- NCT04588727
- Testing
- AZD3366, Ticagrelor, acetylsalicylic acid (ASA)
- Where
- United States
- Volunteers
- 103 people, healthy volunteers welcome
- Sponsor
- AstraZeneca